Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.79 |
| ▸ | NT5E | P21589 | 1/20 | 0.74 |
| ▸ | KRAS | P01116 | 5/20 | 0.74 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.73 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.67 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.67 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.63 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.62 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.62 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HINT1 | P49773 | 1/20 | 0.61 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.61 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18769114 | 0.96 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL21067722 | 0.96 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL29429843 | 0.96 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL851357 | 0.96 | TGM2 (0.85) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL25430382 | 0.94 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL6692026 | 0.94 | TGM2 (0.80) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL376139 | 0.93 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL5809658 | 0.93 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL3333959 | 0.93 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL2593095 | 0.93 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2021-01-28 | — | — | US | disclosed |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2020-05-28 | — | — | US | disclosed |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-10-03 | — | — | US | disclosed |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190047984-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-02-14 | — | — | US | disclosed |
| US-10138220-B1 | Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2018-11-27 | — | — | US | disclosed |
| US-9975875-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170362200-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | Theravance Respiratory Compa, LLC | 2017-12-21 | — | — | US | disclosed |
| WO-2005051946-A2 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050113417-A1 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-05-26 | — | — | US | disclosed |
| WO-2004106333-A1 | AZABICYCLOALKANE COMPOUNDS AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242622-A1 | Azabicycloalkane compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-02 | — | — | US | disclosed |
| US-20040209915-A1 | substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| WO-2004074812-A2 | LIBRARY OF BIPHENYL DERIVATIVES USEFUL FOR IDENTIFYING COMPOUNDS HAVING BOTH BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074276-A1 | BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074246-A2 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | TGM2 3871/4885NT5E 1965/4885KRAS 757/4885 |
| US-10138220-B1 | Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | TGM2 4043/4885NT5E 1603/4885KRAS 705/4885 |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | TGM2 3706/4885NT5E 1715/4885KRAS 794/4885 |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | TGM2 3667/4885NT5E 2520/4885KRAS 905/4885 |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | TGM2 3871/4885NT5E 1965/4885KRAS 757/4885 |
| US-20040242622-A1 | Azabicycloalkane compounds | ADRB1, ADRB2, ADRA1B | TGM2 3760/4885NT5E 1482/4885KRAS 430/4885 |
| US-20040209915-A1 | substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB1, ADRB2, ADRA2B | TGM2 4341/4885NT5E 1956/4885KRAS 947/4885 |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | ADRB1, ADRB2, ADRA2B | TGM2 4678/4885NT5E 884/4885KRAS 1435/4885 |
| US-20050113417-A1 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRA2B, ADRB2, ADRB1 | TGM2 4279/4885NT5E 3279/4885KRAS 689/4885 |
| US-20170362200-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2A | TGM2 3722/4885NT5E 1618/4885KRAS 839/4885 |
| US-20190047984-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | TGM2 3863/4885NT5E 1860/4885KRAS 679/4885 |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | TGM2 3871/4885NT5E 1965/4885KRAS 757/4885 |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | TGM2 3840/4885NT5E 1779/4885KRAS 741/4885 |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | ADRA2C, ADRB2, AHR | TGM2 3289/4885NT5E 417/4885KRAS 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.